- Home
- LLYVA vs TFX Comparison
LLYVA vs TFX Comparison
Compare LLYVA & TFX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LLYVA
- TFX
- Stock Information
- Founded
- LLYVA 1991
- TFX 1943
- Country
- LLYVA United States
- TFX United States
- Employees
- LLYVA N/A
- TFX N/A
- Industry
- LLYVA Broadcasting
- TFX Medical/Dental Instruments
- Sector
- LLYVA Industrials
- TFX Health Care
- Exchange
- LLYVA Nasdaq
- TFX Nasdaq
- Market Cap
- LLYVA 6.0B
- TFX 5.9B
- IPO Year
- LLYVA N/A
- TFX N/A
- Fundamental
- Price
- LLYVA $74.03
- TFX $125.15
- Analyst Decision
- LLYVA
- TFX Hold
- Analyst Count
- LLYVA 0
- TFX 10
- Target Price
- LLYVA N/A
- TFX $176.50
- AVG Volume (30 Days)
- LLYVA 121.2K
- TFX 690.7K
- Earning Date
- LLYVA 01-01-0001
- TFX 05-01-2025
- Dividend Yield
- LLYVA N/A
- TFX 1.08%
- EPS Growth
- LLYVA N/A
- TFX N/A
- EPS
- LLYVA N/A
- TFX 3.20
- Revenue
- LLYVA N/A
- TFX $3,010,144,000.00
- Revenue This Year
- LLYVA $7.29
- TFX $1.40
- Revenue Next Year
- LLYVA N/A
- TFX $4.85
- P/E Ratio
- LLYVA N/A
- TFX $39.19
- Revenue Growth
- LLYVA N/A
- TFX 0.29
- 52 Week Low
- LLYVA $32.55
- TFX $121.70
- 52 Week High
- LLYVA $79.63
- TFX $249.91
- Technical
- Relative Strength Index (RSI)
- LLYVA 62.62
- TFX 40.95
- Support Level
- LLYVA $72.41
- TFX $120.06
- Resistance Level
- LLYVA $74.73
- TFX $138.93
- Average True Range (ATR)
- LLYVA 2.00
- TFX 3.82
- MACD
- LLYVA 0.49
- TFX -0.34
- Stochastic Oscillator
- LLYVA 90.76
- TFX 26.97
About LLYVA Liberty Media Corporation Series A Liberty Live
Liberty Live Group would be engaged in the operations of Live Nation, and Liberty Media's planning for that group is to maximize the value of its investment in that company and the other assets attributed to the Liberty Live Group and to use the new Liberty Live common stock to make strategic acquisitions or for other capital raising initiatives.
About TFX Teleflex Incorporated
Teleflex is a Wayne, Pennsylvania-based manufacturer of hospital supplies and medical devices primarily in the bloodstream/vascular and surgical areas. The firm reports results across seven segments: vascular access (24% of 2024 sales), interventional (19%), anesthesia (13%), surgical (15%), interventional urology (11%), original-equipment manufacturing (11%), and other (7%). Geographic exposure for the business is primarily in the US, which accounts for 60% of revenue, with international markets making up the remainder.